Brazil's Butantan aims to supply 40 million doses of its COVID-19 jab by year-end | Inquirer News

Brazil’s Butantan aims to supply 40 million doses of its COVID-19 jab by year-end

/ 11:58 PM May 27, 2021

Brazil's Butantan aims to supply 40 million doses of its COVID-19 jab by year-end

Graves of people who passed away due to the new coronavirus disease (COVID-19) are pictured at the Parque Taruma cemetery in Manaus, Brazil, on May 20, 2021. Picture taken May 20, 2021. REUTERS/Bruno Kelly

BRASILIA — Brazil’s Butantan Institute could supply at least 40 million doses of its own COVID-19 vaccine called Butanvac in the fourth quarter of 2021, said Director Dimas Covas on Thursday.

Speaking before a Senate panel investigating the federal government’s handling of the pandemic, Covas said clinical trials of the new vaccine can be concluded quickly, though they still need to be authorized by Brazilian health regulator Anvisa.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Brazil, Butanvac, COVID-19, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.